Disease of the RETINA as a complication of DIABETES MELLITUS. It is characterized by the progressive microvascular complications, such as ANEURYSM, interretinal EDEMA, and intraocular PATHOLOGIC NEOVASCULARIZATION.
| Excerpt | Reference |
|---|
| "As some forms of diabetic retinopathy are now treatable, early diagnosis and evaluation is increasingly important." | ( , 1977) |
| "The cause of diabetic retinopathy is still unclear." | ( Kohner, EM; Oakley, NW, 1975) |
| "Diabetic retinopathy is one of the leading causes of vision loss in industrialized countries." | ( Mandarino, LJ, 1992) |
| "Thus, diabetic retinopathy is characterized by a wide spectrum of different features containing the parameters of hemostasis." | ( Jütte, A; Keil, E; Schröder, H; Syrbe, G, 1990) |
| "Diabetic retinopathy is the most common cause of human blindness between the ages of 30 and 67 in the industrialized world." | ( Akanuma, Y; Aoki, S; Fukuda, M; Kanazawa, Y; Kasuga, M; Kosaka, K, 1991) |
| "Diabetic retinopathy is a progressive degeneration of the retina that represents one of the major causes of blindness in the developed world." | ( Benfield, P, 1986) |
| "Diabetic retinopathy is currently the most frequent cause of newly-occurring blindness." | ( Beaumont, P; Hollows, FC, 1973) |
| "Diabetic retinopathy is similarly related to sorbitol accumulation and may be prevented or reversed by inhibition of aldose reductase." | ( Cobo, LM; Cogan, DG; Datilis, MB; Kador, PF; Kinoshita, JH; Kupfer, C; Robison, G, 1984) |
| "Diabetic retinopathy is one of the leading causes of blindness in the United States today." | ( Barnes, WE; Eastman, G; Emanuele, N; Evans, L; Freeman, ML; Gergans, G; Kaplan, E; Kelertas, A, 1984) |
| "Diabetic retinopathy is the leading cause of blindness in young adults, ages 20-55." | ( Ferris, FL, 1994) |
| "Diabetic retinopathy is the leading cause of blindness in adults aged 30 to 65 years." | ( Field, LL; McArthur, RG; Ross, S; Stewart, LL, 1993) |
| "Visual loss from diabetic retinopathy is likely to be considerable in Africans." | ( Becker, PJ; Joannou, J; Kalk, WJ; Mahanlal, P; Mahomed, I; Ntsepo, S, 1997) |
| "Pregnant women with diabetic retinopathy are known to be at a higher risk of developing pregnancy-induced hypertension than those without retinopathy." | ( Archer, DB; Best, RM; Chakravarthy, U; Hadden, DR; Hayes, R, 1999) |
| "Diabetic retinopathy is a leading cause of adult vision loss and blindness." | ( Adamis, AP; Aiello, LP; Bursell, SE; Clermont, AC; Khosrof, S; Miyamoto, K; Murata, T; Ogura, Y; Rohan, R, 1999) |
| "We conclude that diabetic retinopathy is not associated with increased plasma homocysteine levels, but plasma homocysteine accumulates, probably owing to reduced glomerular filtration, in diabetic patients with signs of nephropathy." | ( Agardh, CD; Agardh, E; Hultberg, B, 2000) |
| "Diabetic retinopathy is progressive, and detection early is essential for the prevention of blindness." | ( Denninghoff, KR; Hillman, L; Smith, MH, 2000) |
| "Diabetic retinopathy is the leading cause of blindness in working age individuals in the United States." | ( Gaylord, GM; Haselton, FR; Russ, PK, 2001) |
| "The diabetic retinopathy is one of handicaping complications of diabetics." | ( Ba, EH; Cisse, A; De Medeiros, M; Kameni, A; Ndiaye, MR; Ndiaye, PA; Ndoye-Roth, PA; Seye-Ndiaye, C; Wade, A; Wane, A, 1999) |
| "Diabetic retinopathy is a highly specific vascular complication of both type 1 and type 2 diabetes, estimated to be the most frequent cause of new cases of blindness in the working population of the Western world." | ( Giusti, C, 2002) |
| "Proliferative diabetic retinopathy is more common in insulin dependent diabetes mellitus than in non-insulin dependent diabetes mellitus of more than 25 years of duration." | ( Banerjee, S; Biswas, G; Biswas, MC; Dutta, S; Mandal, S; Saha, SJ, 2002) |
| "Diabetic retinopathy is one of the most debilitating complications of diabetes mellitus." | ( Aiello, LP, 2002) |
| "Diabetic retinopathy is associated with a number of systemic risk factors, namely hyperglycaemia, elevated blood pressure and dyslipidaemia." | ( Chew, EY, 2003) |
| "Diabetic retinopathy is the primary cause of blindness in developed countries, and though strict glycemic control is desirable to prevent complications, this is not always achievable." | ( Araiz, J; Bosch-Morell, F; Johnsen, S; Miranda, M; Muriach, M; Romá, J; Romero, FJ, 2004) |
| "Diabetic retinopathy is a leading cause of adult vision loss and blindness." | ( Adamis, AP; Esser, C; Fauser, S; Janicki, H; Joussen, AM; Kern, TS; Kirchhof, B; Kociok, N; Koizumi, K; Le, ML; Poulaki, V; Schraermeyer, U, 2004) |
| "Diabetic retinopathy is the commonest complication of diabetes and is the biggest single cause of registered blindness in the UK." | ( Butt, A; Hamaoui, K; Powrie, J; Swaminathan, R, 2004) |
| "Diabetic retinopathy is a frequent microvascular complication." | ( Boehm, BO; Kientsch-Engel, R; Lang, GE; Lang, GK; Rosinger, S; Schilling, S; Stahl, P, 2004) |
| "Diabetic retinopathy is associated with IMT and AI, suggesting that common pathogenic mechanisms might predispose to diabetic micro- and macroangiopathy." | ( Deepa, R; Mohan, V; Ravikumar, R; Rema, M, 2004) |
| "Diabetic retinopathy is the leading cause of new blindness in adults in developed countries." | ( Fujio, Y; Nakao, K; Ogawa, Y; Oh, H; Ohashi, H; Ojima, T; Suganami, E; Suganami, T; Suzuma, I; Suzuma, K; Takagi, H; Watanabe, D; Yoshimura, N, 2004) |
| "Diabetic retinopathy is shown to share many similarities with chronic inflammatory disease, and in diabetes, accelerated apoptosis of retinal capillary cells is evident before histopathology can be seen." | ( Kowluru, RA; Odenbach, S, 2004) |
| "Diabetic retinopathy is a disease based on vascular genesis that begins as microangiopathy and develops into macroangioapthy preceded by fibroproliferation changes." | ( Pavljasević, S; Pranjić, N; Sarajlić, D, 2004) |
| "Diabetic retinopathy is the leading cause of blindness in working-age adults." | ( Afzal, A; Brooks, HL; Butler, JM; Caballero, S; Grant, MB; Guthrie, SM; Koc, M; Mames, RN; Scott, EW; Segal, MS, 2005) |
| "Diabetic retinopathy is the commonest cause of blindness between 4th and 7th decades." | ( Tewari, HK; Venkatesh, P, 2004) |
| "Diabetic retinopathy is caused by capillary occlusions." | ( Arichi, M; Imaizumi, M; Matsumura, M; Matsuoka, M; Nomura, S; Ogata, N; Shozu, A, 2005) |
| "The incidence of diabetic retinopathy is still increasing in developed countries." | ( Chiavaroli, C; Garay, RP; Hannaert, P, 2005) |
| "Diabetic retinopathy is a common and potentially devastating microvascular complication in diabetes and is a leading cause of acquired blindness among the people of occupational age." | ( Matsui, T; Nakamura, K; Sato, T; Takeuchi, M; Yamagishi, S, 2006) |
| "Diabetic retinopathy is a common complication of diabetes." | ( Rema, M; Srivastava, BK, 2005) |
| "Diabetic retinopathy is characterized by blood-retinal barrier (BRB) breakdown and neurotoxicity." | ( Al-Shabrawey, M; Caldwell, RB; El-Remessy, AB; Khalifa, Y; Liou, GI; Tsai, NT, 2006) |
| "Diabetic retinopathy is characterized by both functional and morphological changes in the retinal microvessels that can lead to macular edema, neovascularization, and vision loss." | ( Bursell, SE; Clermont, A; Feener, EP, 2006) |
| "Diabetic retinopathy is fast emerging as a leading cause of newly diagnosed legal blindness amongst the working population." | ( Kim, R; Vedantham, V, 2006) |
| "Diabetic retinopathy is a micro-angiopathy affecting predominantly small vessels of the retina." | ( Adamiec, J; Gacka, M, 2006) |
| "Diabetic retinopathy is a leading cause of blindness among adults in the western countries." | ( Ambrósio, AF; Carvalho, CM; Cristóvão, AJ; Santiago, AR; Santos, PF, 2007) |
| "The pathogenesis of diabetic retinopathy is still unclear." | ( Akter, K; Ali, L; Bhuiyan, ZI; Goswami, MK; Rahman, HS; Subhan, SS, 2007) |
| "Diabetic retinopathy is a leading cause of visual disturbance in adults." | ( Kurimoto, M; Murakami, T; Ohashi, H; Ojima, T; Suzuma, I; Suzuma, K; Takagi, H; Watanabe, D, 2007) |
| "Diabetic retinopathy is one of the most devastating microvascular complications of long standing type 1 and type 2 diabetes." | ( Mrudula, T; Reddy, GB; Srinivas, PN; Suryanarayana, P, 2007) |
| "Diabetic retinopathy is a leading cause of vision loss." | ( Arroyo, J; Bertram, K; Erie, JC; Lu, MJ; Pulido, JE; Pulido, JS; Shippy, SA, 2007) |
| "Laser treatment for diabetic retinopathy is often associated with visual field reduction and other ocular side-effects." | ( Colman, PG; Crimet, DC; d'Emden, MC; Davis, TM; Keech, AC; Laatikainen, LT; Merrifield, A; Mitchell, P; Moffitt, MS; O'Connell, RL; O'Day, J; Simes, RJ; Summanen, PA; Taskinen, MR; Tse, D; Williamson, E, 2007) |
| "Diabetic retinopathy is associated with accumulation of advanced glycation end products in the retinal microvasculature." | ( Bhatwadekar, A; Figarola, JL; Gardiner, TA; Glenn, JV; Rahbar, S; Scott, S; Stitt, AW, 2008) |
| "Early diabetic retinopathy is characterized by changes in subtle visual functions such as contrast sensitivity and dark adaptation." | ( Ambrósio, AF; Hughes, JM; Kamphuis, W; Santiago, AR; Schlingemann, RO, 2008) |
| "Diabetic retinopathy is a common and potentially devastating microvascular complication in diabetes and is a leading cause of acquired blindness among the people of occupational age." | ( Matsui, T; Nakamura, K; Okuda, S; Ueda, S; Yamagishi, S, 2008) |
| "The diabetic retinopathy is the leading cause of blindness in patients aged 20-65 years." | ( Gaal, V; Juricskay, I; Kesmarky, G; Koltai, K; Toth, A; Vekasi, J, 2008) |
| "Diabetic retinopathy is a major complication of diabetes and results in death of both neural and vascular cells." | ( Hata, N; Oshitari, T; Yamamoto, S, 2008) |
| "Diabetic retinopathy is one of the most common complications in diabetes mellitus due to persistent hyperglycaemia." | ( Baidya, KP; Bandyopadhyay, R; Bhaduri, G; Bhattacharya, B; Mondal, LK, 2008) |
| "Diabetic retinopathy is associated with a decrease in tyrosine phosphorylation of many vitreous proteins which may indicate an alteration in protein functionality or action even before significant quantitative variations." | ( Abengoechea, S; Ballester, J; Elizalde, J; Fernández-Novell, JM; Guinovart, JJ; Nadal, J; Ramió-Lluch, L; Reverter, JL; Rivera, MM; Rodríguez-Gil, JE, 2009) |
| "Diabetic retinopathy is the leading cause of blindness and visual disability in the industrialized world." | ( Kern, TS; Zheng, L, 2009) |
| "Diabetic retinopathy is a chronic low-grade inflammatory disease; however, the mechanisms remain elusive." | ( Li, J; Wang, JJ; Wang, M; Yu, Q; Zhang, SX, 2009) |
| "Diabetic retinopathy is the leading cause of vision loss or blindeness in working-age adults in the developed and developing countries." | ( Emmerich, KH; Erbler, H; Goldsteine, J; Görtelmeyer, R; Klindzane, M; Poritis, N; Stelmane, I, 2009) |
| "Severe forms of diabetic retinopathy are associated with elevated serum ADMA, SDMA, and l-arginine." | ( Abhary, S; Burdon, KP; Craig, JE; Kasmeridis, N; Kuot, A; Petrovsky, N; Whiting, MJ; Yew, WP, 2009) |
| "Diabetic retinopathy is the most common microvascular complication caused by diabetes mellitus and is a leading cause of vision loss among working-age adults in developed countries." | ( Bursell, D; Clermont, AC; Feener, EP; Gao, BB; Phipps, JA, 2009) |
| "Diabetic retinopathy is the leading cause of blindness in those of working age in the world." | ( Baradaran, HR; Khamseh, ME; Safarnejad, B, 2009) |
| "Diabetic retinopathy is characterized by pathological retinal neovascularization." | ( Annex, BH; Goldschmidt-Clermont, PJ; Li, Y; Liu, X; Liu, Y; Luo, Y; Wang, D, 2010) |
| "Diabetic retinopathy is a progressive neurodegenerative disease, but the underlying mechanism is still obscure." | ( Ishida, S; Kobayashi, S; Kubota, S; Kurihara, T; Noda, K; Ozawa, Y; Sasaki, M; Tsubota, K; Yuki, K, 2010) |
| "Diabetic retinopathy is the result of increased oxidative and nitrosative stress induced by chronic hyperglycaemia, and affects the vasculature and the neuroglia." | ( Dorn-Beineke, A; Feng, Y; Hammes, HP; Lin, J; Pfister, F; vom Hagen, F; Wang, Q, 2010) |
| "Diabetic retinopathy is characterized by morphological changes in the retina secondary to disturbances in retinal blood flow." | ( Bek, T; Erlandsen, M; Jeppesen, P; Mehlsen, J; Poulsen, PL, 2011) |
| "Diabetic retinopathy is a common complication of diabetes, which is caused by injury to retinal microvasculature and neurons." | ( Dong, F; Li, K; Yan, X; Yang, Z; Zhao, C, 2010) |
| "Diabetic retinopathy is the leading cause of blindness to working-age adults." | ( Jiang, Y; Kern, TS; Steinle, JJ; Walker, RJ, 2010) |
| "Diabetic retinopathy is the most common microvascular complication of diabetes and the most severe of diabetic ocular complications." | ( Kador, PF; Obrosova, IG, 2011) |
| "Diabetic retinopathy is one of the most devastating complications in diabetes although little is known with regards to the HPA activity in type 2 diabetic patients (T2DM) with diabetic retinopathy." | ( Amat, N; Chen, X; Eziz, R; Haji, H; Haxim, M; Li, L; Obulkasim, M; Ren, J; Turdi, A; Upur, H, 2011) |
| "Proliferative diabetic retinopathy is associated with concomitant and simultaneous changes in both tyrosine phosphorylation and tyrosine nitrosylation status of specific pro-inflammatory interleukins present in the vitreous fluid such as IL-1α, IL-1β and IL-7." | ( Abengoechea, S; Ballester, J; Elizalde, J; Fernández-Novell, JM; Nadal, J; Ramió-Lluch, L; Reverter, JL; Rivera, MM; Rodriguez, JE, 2011) |
| "Diabetic retinopathy is a microvascular complication of diabetes mellitus whose prevalence is closely related to the presence of nephropathy and hypertension." | ( Auyanet, I; Bosch, E; Cabrera, F; Cardona, P; Checa, MD; Esparza, N; Rodríguez, LJ; Sánchez, AY, 2011) |
| "Diabetic retinopathy is the most common cause of vision loss in young adults in developed countries." | ( Marek, N; Myśliwiec, M; Myśliwska, J; Raczyńska, K; Reiwer-Gostomska, M; Siebert, J; Trzonkowski, P; Zorena, K, 2011) |
| "Diabetic retinopathy is characterized by pericyte loss and vasoregression both in the clinic and in animal models." | ( Berrone, E; Busch, S; Dorn-Beineke, A; Feng, Y; Gorbey, S; Hammes, HP; Höger, S; Korff, T; Krügel, K; Lin, J; Pfister, F; Reichenbach, A; Wang, Q; Wu, L, 2011) |
| "Diabetic retinopathy is characterised by morphological lesions secondary to retinal vascular impairment, and it is assumed that changes in the diameter regulation of retinal arterioles are involved in the disease pathogenesis." | ( Bek, T; Tilma, KK, 2012) |
| "Proliferative diabetic retinopathy is characterized by pathological retinal neovascularization, mediated by both angiogenesis (involving mature endothelial cells) and vasculogenesis (involving bone marrow-derived circulating endothelial progenitor cells (EPCs))." | ( Farjo, K; Ihnat, M; Longeras, R; Ma, JX, 2012) |
| "Diabetic retinopathy is the leading cause of blindness in the working population of the developed countries and also a significant cause of blindness in the elderly." | ( Cai, J; Li, R; Liu, Y; Sun, X; Wang, R; Xiao, X; Xu, J; Xu, W, 2012) |
| "Diabetic retinopathy is a preventable microvascular diabetic complication that damages human retinal pigment epithelial cells." | ( Huang, TH; Roufogalis, BD; Salam, NK; Song, MK, 2011) |
| "Early diabetic retinopathy is characterized by a loss of pericytes from retinal capillaries, the appearance of acellular capillaries and microaneurysms, and a breakdown of the blood-retinal barrier." | ( Brownstein, S; Milne, R, 2013) |
| "The risk of diabetic retinopathy is associated with the presence of both oxidative stress and toxic eicosanoids." | ( He, C; Li, H; Lin, M; Lyons, TJ; Xie, Z; Zou, MH, 2011) |
| "Diabetic retinopathy is characterized by numerous retinal defects affecting the vasculature and the neuro-retina, but the relative contributions of the loss of retinal insulin signaling and hyperglycemia have never been directly compared." | ( Abcouwer, SF; Barber, AJ; Fort, PE; Gardner, TW; Losiewicz, MK; Nakamura, M; Reiter, CE; Singh, RS, 2011) |
| "Diabetic retinopathy is the most common diabetic eye disease, occurring in about 60% of type 2 diabetic patients." | ( Chua, KH; Fong, KC; Koay, AC; Kuppusamy, UR; Ng, ZX; Poh, R; Tajunisah, I, 2012) |
| "Diabetic retinopathy is a complex disease that has potential involvement of inflammatory and oxidative stress-related pathways in its pathogenesis." | ( Bucolo, C; Drago, F; Leggio, GM; Salomone, S, 2012) |
| "Diabetic retinopathy is one of the major complications of diabetes mellitus and a leading cause of visual loss." | ( Lang, GE, 2012) |
| "Diabetic retinopathy is the leading cause of blindness in working age individuals in developed countries." | ( Stewart, MW, 2012) |
| "Diabetic retinopathy is one of the most common and severe complications of diabetes mellitus." | ( Li, CW; Li, ZH; Lu, LC; Luo, MH; Xie, H; Yu, CP; Zhou, W, 2012) |
| "Diabetic retinopathy is a common complication of diabetes mellitus (DM)." | ( Fujii, I; Matsukura, M; Shinohara, M; Xie, P; Zhao, J, 2012) |
| "Diabetic retinopathy is a complex disease that has potential involvement of inflammatory in its pathogenesis." | ( Bian, J; Fu, Y; Ge, Y; Ji, J; Su, L; Yuan, Z, 2012) |
| "Diabetic retinopathy is a complex disease that potentially involves increased production of advanced glycosylation end products (AGEs) and elevated aldose reductase (AR) activity, which are related with oxidative stress and inflammation." | ( Guo, C; Li, F; Liao, S; Mi, H; Qi, D; Shi, X; Yang, Z; Zhang, C, 2012) |
| "Diabetic retinopathy is a common diabetic eye disease caused by changes in retinal ganglion cells (RGCs)." | ( Dong, LY; Jin, J; Kang, XL; Lu, G, 2013) |
| "Diabetic retinopathy is one of the leading causes of blindness and the most common complication of diabetes with no cure available." | ( Alberghina, M; Anfuso, CD; Bucolo, C; Drago, F; Giurdanella, G; Lupo, G; Motta, C; Salomone, S, 2013) |
| "Diabetic retinopathy is characterized by morphological lesions in the retina secondary to disturbances in retinal blood flow which may influence the supply of oxygen to the retinal metabolism." | ( Bek, T; Hardarson, SH; Jørgensen, CM, 2014) |
| "Diabetic retinopathy is a leading cause of blindness worldwide." | ( Hart, GW; Huang, H; Lutty, GA; Semba, RD; Van Eyk, JE, 2014) |
| "The diabetic retinopathy is a neurovascular complication of diabetes mellitus and it is the leading cause of vision loss among working adults worldwide." | ( Avitabile, T; Bucolo, C; Caraci, F; Drago, F; Gagliano, C; Giordano, M; Malaguarnera, G; Motta, M; Reibaldi, M; Salomone, S; Vacante, M, 2014) |
| "Diabetic retinopathy is a common diabetic eye disease caused by changes in retinal ganglion cells (RGCs)." | ( Jia, WC; Liu, G; Zhang, CD; Zhang, SP, 2014) |
| "Diabetic retinopathy is characterized by retinal vascular impairment resulting in retinal hypoxia." | ( Bek, T; Jørgensen, C, 2014) |
| "Diabetic retinopathy is the most common complications of diabetes mellitus that, in most occasions, lead to blindness." | ( Adam, AM; Elamin, MI; Hamdan, HZ; Nasser, NM; Saleem, MA, 2015) |
| "Diabetic retinopathy is widely recognized as a neurodegenerative disease of the eye." | ( Abuohashish, HM; Ahmad, R; Ahmed, MM; Al-Rejaie, SS; Alhomida, AS; Ola, MS, 2015) |
| "Diabetic retinopathy is characterized by progressive vision loss and the advancement of retinal micoraneurysms, edema and angiogenesis." | ( Alam, NM; Douglas, RM; Mills, WC; Prusky, GT; Szeto, HH; Wong, AA, 2015) |
| "Diabetic retinopathy is the leading cause of vision loss in working-age adults; it is a highly prevalent cause of vision loss overall and has a potent impact on the quality of life in those with diabetes mellitus and public health in general." | ( Colucciello, M, 2015) |
| "Diabetic retinopathy is an ocular complication associated with the chronic endocrine disorder of diabetes mellitus." | ( Behl, T; Goel, H; Kaur, I; Kotwani, A, 2017) |
| "Diabetic retinopathy is a significant cause of vision impairment, especially affecting those of working age." | ( Newman, D; Ong, J; Ooi, JL; Sharma, N, 2015) |
| "Diabetic retinopathy is a leading cause of reduced visual acuity and acquired blindness." | ( Aranda, ML; Dorfman, D; Rosenstein, RE, 2015) |
| "Diabetic retinopathy is associated with enhanced oxidative stress and/or reduction of antioxidant status." | ( Karalezli, A; Kulaksızoglu, S, 2016) |
| "Human diabetic retinopathy is characterized by the basement membrane thick, pericytes loss, microaneurysms formation, retina neovascularization and vitreous hemorrhage." | ( Chen, F; Fan, Y; Luo, DW; Sun, T; Sun, Y; Wang, H; Wang, WJ; Xu, X; Zheng, Z, 2015) |
| "Diabetic retinopathy is a major diabetic complication predominantly caused by vascular endothelial growth factor (VEGF)-induced vascular permeability in the retina; however, treatments targeting glycemic control have not been successful." | ( Choi, YE; Ha, KS; Han, JY; Hong, HD; Hwang, J; Jeon, HY; Jung, SH; Kim, SH; Kim, YM; Lee, YJ; Na, S, 2015) |
| "Diabetic retinopathy is a microvascular complication of diabetes, and is one of the leading causes of blindness in the UK working age population." | ( Bicknell, C; Darzi, A; Gunn, L; Judah, G; King, D; Valabhji, J; Vlaev, I, 2016) |
| "Early diabetic retinopathy is characterized by a loss of pericytes and vascular endothelial cells, a breakdown of the blood-retinal barrier, vascular dysfunction and vascular-neuroinflammation." | ( Wang, Y; Yan, H, 2016) |
| "Diabetic retinopathy is a leading cause of blindness." | ( Feng, D; Li, L; Li, Y; Li, Z; Sheng, J; Wang, A; Wang, F; Yin, F; Zhang, X, 2016) |
| "Diabetic retinopathy is a common complication of type 2 diabetes and the leading cause of blindness in adults of working age." | ( Azaiz, R; Baccouche, B; Ben Chaouacha-Chekir, R; Charfeddine, R; Dellaa, A; Dubus, E; Hammoum, I; Mbarek, S; Picaud, S, 2017) |
| "Diabetic retinopathy is accompanied with changes in the diameter regulation and oxygenation of retinal vessels." | ( Bek, T; Petersen, L, 2016) |
| "Diabetic retinopathy is a common microvascular complication of long-standing diabetes." | ( Agarwal, R; Dongare, S; Gupta, SK; Kumar, P; Mathur, R; Mathur, S; Nag, TC; Saxena, R; Srivastava, S, 2016) |
| "Diabetic retinopathy is considered a microvascular disease, but recent evidence has underlined early involvement of the neuroretina with interactions between microvascular and neural alterations." | ( Arroba, AI; Beltramo, E; Hernández, C; Lopatina, T; Mazzeo, A; Porta, M; Simó, R; Valverde, AM, 2016) |
| "Diabetic retinopathy is characterised by morphological lesions in the ocular fundus related to disturbances in retinal blood flow." | ( Bek, T; Jørgensen, CM, 2017) |
| "Diabetic retinopathy is one of the most common consequences of diabetes that affects millions of working-age adults worldwide and leads to progressive degeneration of the retina, visual loss, and blindness." | ( Bennis, M; Cooper, HM; Coutanson, C; Dkhissi-Benyahya, O; Lahouaoui, H, 2016) |
| "Diabetic retinopathy is the leading cause of blindness in working age adults, and is projected to be a significant future health concern due to the rising incidence of diabetes." | ( Antonetti, DA; Bolinger, MT, 2016) |
| "Diabetic retinopathy is the most common complication in diabetic patients relates to high expression of VEGF and microaneurysms." | ( Chen, L; Deng, DY; Huang, P; Long, L; Luo, J; Tan, J; Wang, J; Yang, L; Zhang, LM; Zhou, W; Zhu, B, 2017) |
| "Diabetic retinopathy is common and increasing in prevalence." | ( Wykoff, CC, 2017) |
| "Since diabetic retinopathy is characterized by increased vascular permeability in its early pathogenesis, RA normalized retinal astrocytes that are compromised in diabetes, resulting in suppression of vascular leakiness." | ( Osanai, M, 2017) |
| "Diabetic retinopathy is a serious sight-threatening complication which is manifested by excessive angiogenesis in diabetic patients." | ( Caprnda, M; Kobyliak, N; Kruzliak, P; Kubatka, P; Saxena, S; Stefanickova, J; Valaskova, J; Zulli, A, 2017) |
| "Diabetic retinopathy is a severe retinal complication that diabetic patients are susceptible to present." | ( Calaza, KC; Carpi-Santos, R; Maggesissi, RS; von Seehausen, MP, 2017) |
| "Diabetic retinopathy is a common complication of diabetes mellitus." | ( Ma, JX; Malechka, VV; Moiseyev, G; Shin, Y; Takahashi, Y, 2017) |
| "Diabetic retinopathy is a neurological disease, which can lead to blindness in severe cases." | ( Cai, D; Chen, C; Chen, J; Chen, Z; Lin, S; Wu, L; Zhang, J, 2018) |
| "Diabetic retinopathy is a neurovascular disease characterized by increased permeability of the blood-retinal barrier, changes in the neural components of the retina, and low-grade chronic inflammation." | ( Alves, MRP; Ambrósio, AF; Baptista, FI; Boia, R; Campos, EJ; Madeira, MH; Martins, J; Nunes, S; Pereira, FC; Reis, F; Santiago, AR, 2018) |
| "A major feature of diabetic retinopathy is breakdown of the blood-retinal barrier, resulting in macular oedema." | ( Chan-Ling, T; Coleman, P; Gamble, JR; Gillies, M; Li, J; Moller, T; Shen, W; Ting, KK; Vadas, MA; Yam, M; Zhao, Y, 2019) |
| "Diabetic retinopathy is one of the major causes of blindness and the number of cases has risen in recent years." | ( Grant, SJ; Li, G; Wan, X; Zhang, H; Zhang, HW, 2018) |
| "Diabetic Retinopathy is the medical term for denoting the damages to retina caused due to diabetes mellitus." | ( Dhivyaa, CR; Vijayakumar, M, 2019) |
| "Diabetic retinopathy is a diabetes complication." | ( Jiang, M; Tao, J; Wang, Y; Yao, Y, 2019) |
| "Diabetic retinopathy is characterized by disturbances in retinal blood flow mediated by capillary occlusion, intraretinal microvascular abnormalities (IRMAs), neovascularizations, and omega loops and reduplications." | ( Bek, T; Petersen, L, 2019) |
| "Diabetic retinopathy is a major complication of diabetes." | ( Liu, Z; Xiao, H, 2019) |
| "Diabetic retinopathy is characterised by morphological lesions in the retina secondary to disturbances in retinal blood flow." | ( Bek, T; Tilma, KK, 2020) |
| "Diabetic retinopathy is the most common microvascular complication of diabetes, and in the advanced diabetic retinopathy appear vitreal fibrovascular membranes that consist of a variety of cells, including vascular endothelial cells (ECs)." | ( Cui, J; Han, H; Huang, X; Jiang, H; Kazlauskas, A; Lei, H; Matsubara, JA; Mukai, S; Vanhaesebroeck, B; Wang, J; Wu, W; Xia, X; Zhou, G, 2020) |
| "Diabetic retinopathy is emerging as an important cause of avoidable visual impairment and blindness in India across all strata of society." | ( Desai, AK; Deshpande, M; Naik, VS; Shukla, R; Usgaonkar, UPS, 2020) |
| "Diabetic retinopathy is thought to be trigger by glucose- induced oxidative stress which leads to an increase of the mitochondrial permeability through opening the permeability transition pore (MTP)." | ( Ramírez-Pérez, G; Salceda, R; Sánchez-Chávez, G, 2020) |
| "Diabetic retinopathy is a diabetes-mediated retinal microvascular disease that is the leading cause of blindness in the working-age population worldwide." | ( Howell, SJ; Lee, CA; Lindstrom, SI; Tang, J; Taylor, BE; Taylor, PR; Taylor, ZRR; Zapadka, TE, 2020) |
| "Diabetic retinopathy is a severe diabetic complication and a major cause of blindness." | ( Liu, J; Zeng, Q, 2020) |
| "Diabetic retinopathy is one of the leading causes of visual impairment after cataract and uncorrected refractive error." | ( Kumar, G; Kumar, S; Pardhan, S; Raman, R; Ruamviboonsuk, P; Sivaprasad, S; Velu, S, 2020) |
| "Diabetic retinopathy is a serious complication of diabetes, marked by retinal vascular damage, inflammation, and angiogenesis." | ( Jain, M; Joharapurkar, A; Kshirsagar, S; Patel, MS; Patel, V; Savsani, H, 2021) |
| "Diabetic retinopathy is a multifactorial microvascular complication, and its pathogenesis hasn't been fully elucidated." | ( Hu, P; Jiang, X; Liu, G; Tong, X; Wang, Y; Wu, F; Wu, H, 2021) |
| "Diabetic retinopathy is the leading cause of blindness which is associated with excessive angiogenesis." | ( Been, JH; Cho, J; Choi, K; Choi, S; Choi, SW; Han, J; Jiang, W; Kim, D; Kim, KL; Kim, S; Lee, SK; Oh, J; Park, C; Seo, S; Suh, W, 2021) |
| "Diabetic retinopathy is the leading cause of blindness in the working-age population worldwide." | ( Batoki, JC; Howell, SJ; Lee, CA; Lindstrom, SI; Taylor, BE; Taylor, PR; Zapadka, TE, 2021) |
| "Diabetic retinopathy is a major cause of preventable sight loss in the working-age population and a major global health issue." | ( Seewoodhary, M, 2021) |
| "Diabetic retinopathy is a frequent complication of diabetes mellitus and one of the common causes of blindness." | ( Ling, L; Xu, H; Zhang, Y; Zheng, L, 2021) |
| "Diabetic retinopathy is one of the most common and serious complications of diabetes, and an established risk factor for blindness in adults." | ( Di Virgilio, F; Scialdone, A; Solini, A; Tassetto, M, 2021) |
| "Diabetic retinopathy is one of the most common causes of blindness in work-aging adults and develops in one third of diabetic patients." | ( Akbari, M; Ashraf, H; Ghaffari, M; Jahanbani-Ardakani, H; Khalili, MR; Lotfi, M, 2021) |
| "Diabetic retinopathy is a vision-threatening complication of diabetes characterized by endothelial injury and vascular dysfunction." | ( Cruz-Topete, D; Harris, NR; Hartson, SD; Kaur, G; Pattillo, CB; Rashdan, NA; Rogers, J, 2021) |
| "Diabetic retinopathy is the major vision-threatening complication of diabetes." | ( Aloysius Dhivya, M; Bharathi Devi, SR; Sulochana, KN, 2022) |
| "Diabetic retinopathy is a complication of diabetes, caused by high blood sugar levels damaging the retina." | ( Li, J; Ma, H, 2022) |
| "Diabetic retinopathy is a leading cause of vision impairment." | ( Indumathi, A; Jayashree, K; Ramesh Babu, K; Senthilkumar, GP, 2022) |
| "Diabetic retinopathy is a common complication of type 2 diabetes mellitus (T2DM)." | ( Fang, ZZ; Gao, XQ; Li, X; Liu, X; Wang, WY, 2022) |
| "Diabetic retinopathy is one of the serious complications of diabetes, which the leading causes of blindness worldwide, and its irreversibility renders the existing treatment methods unsatisfactory." | ( Han, Y; Kong, L; Sun, H; Sun, Y; Wang, XJ; Yan, GL; Zhang, AH, 2022) |
| "Diabetic retinopathy is a disease seen with microvascular complications as a result of hyperglycemia and insulin resistance." | ( Akkoç, RF; Aydin, S; Çelik, F; Gül, FC; Kobat, SG, 2022) |
| "Diabetic retinopathy is a major cause of blindness in developed countries, and is characterized by deterioration of barrier function causing vascular hyperpermeability and retinal edema." | ( Harimoto, K; Ito, M; Nishio, Y; Sato, T; Someya, H; Takeuchi, M, 2022) |
| "Diabetic retinopathy is a diabetic microvascular complication." | ( Ding, L; Liu, D; Wang, N; Xia, X; Xiong, S; Zhang, Q; Zheng, G, 2022) |
| "Diabetic retinopathy is a severe microvascular problem in diabetes mellitus." | ( Abazari, O; Bakhshi, A; Dayati, P; Kafi, E; Karimi, R; Naghib, SM; Rahmanian, M; Savaee, M; Shahidi, M, 2022) |
| "Diabetic retinopathy is the most common reason for blindness among employed adults worldwide." | ( Cai, Y; Cheng, F; Cong, W; Deng, J; Deng, Y; Yan, J; Zhang, T, 2023) |
| "Diabetic retinopathy is the most feared complication for those with diabetes." | ( Dixon, MA; Fletcher, EL; Jobling, AI; Mills, SA, 2023) |
| "Diabetic retinopathy is one of the most common microvascular complications of diabetes." | ( Jiang, Y; Luo, B, 2023) |
| "Diabetic retinopathy is a frequent complication of diabetes mellitus and a leading cause of blindness in adults." | ( Alwees, M; Asaad, MA; Dick, HB; Joachim, SC; Kakkassery, V; Schultz, T; Theile, J; Tsai, T, 2023) |
| "Diabetic retinopathy is a common microvascular complication of diabetes mellitus." | ( Cheng, Y; Fan, H; Liu, J; Liu, K; You, Z; Zou, H, 2023) |
| "Diabetic retinopathy is a typical complication of diabetes, which can facilitate the risk of blindness in severe cases." | ( Fan, F; Pan, Z; Wang, J; Zhao, Y; Zhou, S, 2023) |
| "Diabetic retinopathy is a leading cause of blindness in working-age adults worldwide." | ( Aaberg, MT; Bommakanti, N; Patel, TP; Paulus, YM; Yu, G; Zhao, PY, 2023) |
| Excerpt | Reference |
|---|
| "The Early Treatment Diabetic Retinopathy Study (ETDRS) enrolled 3711 patients with mild-to-severe nonproliferative or early proliferative diabetic retinopathy in both eyes." | ( Barton, FB; Chew, EY; Ferris, FL; Flynn, HW; Remaley, NA; Simons, BD, 1992) |
| "The Early Treatment Diabetic Retinopathy Study, a randomized clinical trial supported by the National Eye Institute, was designed to assess the effect of photocoagulation and aspirin in 3711 patients with mild to severe nonproliferative or early proliferative diabetic retinopathy." | ( Barton, FB; Burton, TC; Chew, EY; Ferris, FL; Remaley, NA; Williams, GA, 1992) |
| "The Early Treatment Diabetic Retinopathy Study (ETDRS), a multicenter collaborative clinical trial supported by the National Eye Institute, was designed to assess whether argon laser photocoagulation or aspirin treatment can reduce the risk of visual loss or slow the progression of diabetic retinopathy in patients with mild-to-severe nonproliferative or early proliferative diabetic retinopathy." | ( , 1991) |
| "The Early Treatment Diabetic Retinopathy Study included use of nonsimultaneous stereoscopic fluorescein angiography to assess severity of characteristics such as capillary loss and fluorescein leakage and to guide treatment of macular edema." | ( , 1991) |
| "In the Early Treatment Diabetic Retinopathy Study, a randomized clinical trial sponsored by the National Eye Institute, one eye of each patient was assigned to early photocoagulation and the other to deferral of photocoagulation (i." | ( , 1991) |
| "In the Early Treatment Diabetic Retinopathy Study (ETDRS), a multicenter clinical trial sponsored by the National Eye Institute, one eye of each patient was assigned randomly to early photocoagulation and the other to deferral of photocoagulation (i." | ( , 1991) |
| "Data from the Early Treatment Diabetic Retinopathy Study (ETDRS) show that focal photocoagulation of "clinically significant" diabetic macular edema substantially reduces the risk of visual loss." | ( , 1985) |
| "The Early Treatment Diabetic Retinopathy Study (ETDRS), a multicenter randomized clinical trial, was designed to assess the effect of photocoagulation and aspirin on 3711 patients with mild to severe nonproliferative or early proliferative diabetic retinopathy." | ( Chew, EY; Ferris, FL; Klein, ML; Murphy, RP; Remaley, NA, 1995) |
| "The Early Treatment Diabetic Retinopathy Study (ETDRS), conducted at 22 clinical centers during the period 1980 to 1989, collected baseline data on C-peptide levels after ingestion of Sustacal in 582 patients with diabetes mellitus, prior to enrollment in the trial." | ( Ewart, R; Kumar, D; Miller, D; Prior, MJ; Prout, T, 1993) |
| "Accommodative amplitudes in Early Treatment Diabetic Retinopathy Study patients were lower than normal accommodative amplitudes." | ( Benson, WE; Braun, CI; Chew, EY; Ferris, FL; Remaley, NA, 1995) |
| "Observational data from the Early Treatment Diabetic Retinopathy Study." | ( Chantry, K; Chew, EY; Ferris, FL; Hoogwerf, BJ; Klein, ML; Miller, D; Murphy, RP; Remaley, NA, 1996) |
| "The observational data from the Early Treatment Diabetic Retinopathy Study suggest that lipid lowering may also decrease the risk of hard exudate formation and associated vision loss in patients with diabetic retinopathy." | ( Chantry, K; Chew, EY; Ferris, FL; Hoogwerf, BJ; Klein, ML; Miller, D; Murphy, RP; Remaley, NA, 1996) |
| "Argon laser treatment of diabetic retinopathy (DR) is the best evaluated case in the field of minimally invasive therapy." | ( Vondeling, H, 1993) |
| "Approximately 50% of the Early Treatment Diabetic Retinopathy Study population had color vision scores (SQRT 100-Hue score) worse than 95% of the normal population reported by Verriest and associates." | ( Barton, FB; Bresnick, GH; Fong, DS, 1999) |
| "The Early Treatment of Diabetic Retinopathy Study chart was used for assessing far-best corrected visual-acuity, and fluorescein angiography was performed using the Heidelberg Retina Angiograph." | ( Forte, R; Gargiulo, P; Giusti, C; Vingolo, EM, 2001) |
| "Early Treatment Diabetic Retinopathy Study patients enrolled in the Johns Hopkins Clinical Center had complete eye examinations, including best-corrected visual acuity measurements, fundus photographs, and medical questionnaires throughout the 7-year study." | ( Agrón, E; Chew, EY; Csaky, KG; Ferris, FL; Murphy, RP; Reed, GF; Schachat, AP; Thompson, DJ, 2003) |
| "Inhibitors of VEGF in treatment of diabetic retinopathy are presented." | ( Peczyńska, J; Urban, B, 2003) |
| "Secondary outcomes were Early Treatment Diabetic Retinopathy Study (ETDRS) scores, intraocular pressure, and cataract progression." | ( Audren, F; Benosman, R; Bergmann, JF; Caulin, C; Erginay, A; Gaudric, A; Haouchine, B; Massin, P, 2004) |
| "Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) scores and clinical changes in macular edema." | ( Kaya, M; Onder, HI; Tunc, M, 2005) |
| "Early Treatment Diabetic Retinopathy Study scores at 18 weeks were 46." | ( Kaya, M; Onder, HI; Tunc, M, 2005) |
| "Patients had an Early Treatment Diabetic Retinopathy Study (ETDRS) retinopathy severity level between 47B and 53E inclusive, an ETDRS visual acuity of 20/125 or better, and no history of scatter (panretinal) photocoagulation." | ( , 2005) |
| "An example from the Early Treatment Diabetic Retinopathy Study (ETDRS) is given." | ( Andrei, AC; Murray, S, 2005) |
| "The predicted change in Early Treatment Diabetic Retinopathy Study letters read at 6 months is 0 for untreated fellow eyes without DME, 0 for eyes receiving focal laser, +3 for eyes receiving IVTA, and -1 for eyes receiving vitrectomy." | ( Browning, DJ; Fraser, CM; Powers, ME, 2006) |
| "Secondary outcomes were gain in Early Treatment Diabetic Retinopathy Study (ETDRS) scores, intraocular pressure (IOP), cataract progression, and duration of effect." | ( Audren, F; Benosman, R; Bergmann, JF; Erginay, A; Gaudric, A; Haouchine, B; Lecleire-Collet, A; Massin, P, 2006) |
| "Pharmacologic treatment of diabetic retinopathy via eyedrops could have advantages but has not been successful to date." | ( Ball, SL; Bingaman, DP; Du, Y; Jamison, JA; Kern, TS; Kim, M; Miller, CM; Mohr, S; Zheng, L, 2007) |
| "Refraction and Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity were also measured before each OCT measurement was taken." | ( Bandello, F; Chiodini, RG; Isola, M; Polini, G; Polito, A; Soldano, F, 2007) |
| "Laser treatment for diabetic retinopathy is often associated with visual field reduction and other ocular side-effects." | ( Colman, PG; Crimet, DC; d'Emden, MC; Davis, TM; Keech, AC; Laatikainen, LT; Merrifield, A; Mitchell, P; Moffitt, MS; O'Connell, RL; O'Day, J; Simes, RJ; Summanen, PA; Taskinen, MR; Tse, D; Williamson, E, 2007) |
| "Ruboxistaurin shows promise as an oral treatment for diabetic retinopathy." | ( Clarke, M; Dodson, PM, 2007) |
| "The Early Treatment Diabetic Retinopathy Study showed a significant benefit in using focal laser photocoagulation for the treatment of macular edema, more specifically defined as clinically significant macular edema." | ( Alfaro, DV; Fernández, M; Gómez-Ulla, F; Marticorena, J; Méndez, ER; Rothen, M, 2006) |
| "No trial evaluated the treatment of diabetic retinopathy with vitamin C or SOD." | ( Atallah, AN; Lopes de Jesus, CC; Moça Trevisani, VF; Valente, O, 2008) |
| "The Early Treatment Diabetic Retinopathy Study showed a significant benefit in using focal laser photocoagulation for the treatment of macular edema, more specifically defined as clinically significant macular edema." | ( Abraldes, MJ; Fernández, M; Gómez-Ulla, F, 2009) |
| "Medical treatment for diabetic retinopathy could have an important role in prevention of complications such as visual loss." | ( Gerss, J; Haritoglou, C; Kampik, A; Sauerland, C; Ulbig, MW, 2009) |
| "Pivotal studies, such as the Early Treatment Diabetic Retinopathy Study and the Diabetic Retinopathy Study, have established laser photocoagulation as the accepted treatment modality." | ( Cortez, MA; Cortez, RT; Giuliari, GP; Guel, DA, 2010) |
| "DR was graded according to Early Treatment Diabetic Retinopathy Study criteria." | ( Benzie, IF; Chan, LY; Choi, SW; Lam, CS; Woo, GC; Yeung, VT, 2011) |
| "An improvement ≥2 steps in the Early Treatment Diabetic Retinopathy Study retinopathy scale occurred in 13." | ( Bailey, C; Billman, K; Boyer, D; Brown, DM; Campochiaro, PA; Chen, S; Garretson, B; Green, K; Gupta, A; Hariprasad, SM; Kane, FE; Kapik, B; Pearson, A; Reichel, E; Ruiz-Moreno, J; Soubrane, G, 2012) |
| "The Early Treatment of Diabetic Retinopathy Study scale was used to assess the severity of retinopathy." | ( Forsblom, C; Gordin, D; Groop, PH; Harjutsalo, V; Hietala, K; Kytö, J; Mäkinen, VP; Summanen, PA; Taskinen, MR; Thorn, LM; Tolonen, N; Wadén, J, 2013) |
| "DR was graded according to the Early Treatment of Diabetic Retinopathy Study (ETDRS) scale, and patients with ETDRS levels 10-35 were included." | ( Cunha-Vaz, J; Frydkjaer-Olsen, U; Grauslund, J; Peto, T; Simó, R; Soegaard Hansen, R, 2016) |
| "Improvement in the treatment of diabetic retinopathy requires a better understanding of the molecular mechanisms that cause neurovascular complications, particularly in type 2 diabetes." | ( Dennis, MD; Kimball, SR; Martin, TD; Miller, WP; Ravi, S, 2017) |
| "Mean preoperative Early Treatment Diabetic Retinopathy Study visual acuity (VA) was 16." | ( Dalla Mura, G; Gusson, E; Panozzo, G; Panozzo, GA, 2017) |
| "Patients with treatment-naïve diabetic retinopathy (DR) undergoing intravitreal dexamethasone implant for DME between October 2015 and March 2017 were enrolled." | ( Bandello, F; Parravano, M; Querques, G; Querques, L; Rabiolo, A; Sacconi, R, 2017) |
| "Visual acuity (VA) in Early Treatment Diabetic Retinopathy Study (ETDRS) letters and central macular thickness (CMT) values on optical coherence tomography were extracted." | ( Eldem, B; Kadayıfçılar, S; Koç, İ, 2018) |
| "Without proper medication for the treatment of diabetic retinopathy, retinal cells become malnourished and degenerate, which results in damage to vision cells and can lead to blindness." | ( Babaie, S; Mehrabadi, ME; Panahi, M; Salemi, Z, 2018) |
| "An efficient medical treatment to reduce diabetic retinopathy can improve the quality of life for diabetes patients." | ( Li, H; Lin, L; Xu, L; Zhang, J, 2019) |
| "For each patient, the BCVA [Early Treatment Diabetic Retinopathy Study (ETDRS) charts] and macular thickness on optical coherence tomography (OCT) at baseline visit and within the 2nd, 4th, and 6th months of follow-up were obtained." | ( Castro-Navarro, V; Cervera-Taulet, E; Hernández-Bel, L; Monferrer-Adsuara, C; Montero-Hernández, J; Navarro-Palop, C, 2019) |
| "At baseline, Early Treatment Diabetic Retinopathy Study levels were 10 (no DR, 42." | ( Cunha-Vaz, J; Fernández-Carneado, J; Frydkjaer-Olsen, U; Grauslund, J; Hernández, C; Peto, T; Ponsati, B; Simó, R, 2019) |
| "Early detection and treatment of diabetic retinopathy necessitates screening." | ( Brazionis, L; Januszewski, A; Jenkins, A; Peto, T; Quinn, N; Ryan, C, 2021) |
| "In Group 1, the mean baseline Early Treatment Diabetic Retinopathy (ETDRS) BCVA letter score was 44." | ( Limon, U, 2021) |
| "Early treatment diabetic retinopathy study (ETDRS) criteria were used to grade fundus photographs." | ( Kaushik, M; Nawaz, S; Qureshi, TS, 2021) |
| "Current treatments for diabetic retinopathy (DR) have considerable limitations, emphasizing the need for new therapeutic options." | ( Qin, YJ; Sun, XF; Xiao, K; Yu, T; Zhao, Y; Zhong, Z, 2022) |
| "MMDHP may be effective for the treatment of diabetic retinopathy through active ingredients luteolin, acacetin, naringenin, and alisol B via AKT1, SRC, and VEGFA in AGE-RAGE, PI3K-AKT, and Rap1 signaling pathways." | ( Fan, G; Xu, L; Zhang, Y; Zhou, Y, 2022) |
| "MMDHP may be effective for the treatment of diabetic retinopathy through active ingredients luteolin, acacetin, naringenin, and alisol B via AKT1, SRC, and VEGFA in AGE-RAGE, PI3K-AKT, and Rap1 signaling pathways." | ( Fan, G; Xu, L; Zhang, Y; Zhou, Y, 2022) |
| "To compare Early Treatment Diabetic Retinopathy Study (ETDRS) diabetic retinopathy (DR) severity on ultrawide field (UWF) colour imaging (CI) and UWF fluorescein angiography (FA)." | ( AbdelAl, O; Aiello, LP; Ashraf, M; Pitoc, CM; Shokrollahi, S; Silva, PS, 2023) |